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ABSTRACT
Somatostatin (SS) and SS receptor (SSR) subtypes, code-named
sst1–5, are heterogeneously expressed in the normal human thymus.
This suggests their involvement in controlling the immune and/or
neuroendocrine functions in this organ. Moreover, recently a high in
vivo uptake of [111In-DTPA-D-Phe1]octreotide has been reported in
patients bearing thymoma. The present study characterizes in vivo
and in vitro, functional SS-binding sites in a human thymoma.
A high uptake of [111In-DTPA-D-Phe1]octreotide was observed in
the chest of a patient with myasthenia gravis due to a cortical thy-
moma. Specific binding of [125I-Tyr11]SS-14 was found on a membrane
preparation of the surgically removed thymoma. Scatchard analysis
showed high affinity binding sites (Kd, 47.5 6 2.5 pmol/L) with low
maximum binding capacity (23.5 6 2.5 fmol/mg membrane protein).
RT-PCR analysis showed the presence of sst1, sst2A, and a predom-
inant sst3 messenger RNA (mRNA) expression in the tumor tissue.
Primary cultured tumor cells expressed sst3 mRNA only. In contrast
to the normal thymus, SS mRNA was not expressed. By immunohis-
tochemistry, the tumor cells highly expressed sst3 receptors, weakly
expressed sst1 receptors, and showed no immunostaining for sst2A
receptors. sst2A immunoreactivity was found in the stromal compart-
ment of the tumor, particularly on the endothelium of small intra-
tumoral blood vessels. In primary cultured tumor cells, both SS and
octreotide (10 nmol/L) significantly inhibited [3H]thymidine incorpo-
ration by 40.6% and 43.2%, respectively.
The following conclusions were reached. 1) As this tumor displayed
a high immunoreactivity for sst3 and the cultured tumor cells ex-
pressed the sst3 mRNA only, this SSR may be the subtype involved
in the inhibition of epithelial tumor cell proliferation by octreotide in
vitro. 2) A loss of endogenous SS production in this thymoma might
be implicated in the uncontrolled cell growth. 3) In this case, the sst3
may play a role in determining the uptake of [111In-DTPA-D-
Phe1]octreotide by in vivo SS receptor scintigraphy. (J Clin Endocri-
nol Metab 85: 1719–1726, 2000)
THE THYMUS is the primary lymphoid organ wherecytokines and thymic hormones participate in regu-
lating the proliferation and differentiation of T cells (1). These
factors are produced by the thymic stroma. The preponder-
ant cell type in the stroma is of epithelial origin, consisting
of at least two distinct subsets, cortical and medullary thymic
epithelial cells (TEC) (2). Recently, attention has been drawn
to the presence of neuroendocrine and peripheral hormones,
which seem to participate in an autocrine and paracrine
manner to the functioning of TEC (3). Some of these hor-
mones have well characterized actions on immune cell dif-
ferentiation and proliferation, whereas others, such as so-
matostatin (SS), have been identified, but not investigated for
their function within the thymus (4).
The biological effects of SS, including the inhibition of
hormone and exocrine secretion as well as the modulation of
neurotransmission and cell proliferation, are mediated
through five different G protein-coupled, high affinity, mem-
brane receptor subtypes (sst1–5) (5, 6). SS receptors (SSR) have
been demonstrated in normal tissues and in many tumors at
the protein and messenger ribonucleic acid (mRNA) levels
by receptor binding studies on tissue homogenates, by in vivo
and in vitro SSR autoradiography, by in situ hybridization, as
well as by RT-PCR (7, 8). Furthermore, SSR subtypes have
been localized at the cellular level by immunohistochemistry
using a specific antipeptide antibody in a series of human
tumors and in normal human pancreas as well (9–13). Lo-
calization studies of SSR on specific cell types within SSR-
positive tissues demonstrated heterogeneity of receptor dis-
tribution (14).
Octreotide, an octapeptide SS analog, binds with high
affinity to sst2 and with a relatively lower affinity to sst3 and
sst5 (15). Imaging techniques with [
111In-DTPA-d-
Phe1]octreotide have visualized SSR in various human neo-
plasms in vivo. In many cases, a positive scan predicts a good
response to treatment with octreotide (16, 17).
We have recently characterized the SS and SSR subtype
distribution pattern within the normal human thymus (18).
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SS and sst1, sst2A, and sst3 mRNAs were found in thymic
tissue, whereas enriched cultured TEC selectively express
sst1 and sst2A as well as SS mRNA (18). Moreover, successful
treatments with octreotide have been reported in two pa-
tients with thymoma (19, 20). To unravel the functional sig-
nificance of SSR in human thymomas, we investigated in the
present study the expression and functional role of SS and
SSR subtypes in a cortical thymoma. In vivo SSR scintigraphy
was performed in a patient admitted for myasthenia gravis.
SSR expression on the tumor tissue was investigated using
in vitro SSR binding studies, RT-PCR, and immunohisto-
chemistry. Moreover, the effects of SS and octreotide on cell
proliferation were evaluated in a primary cell culture of the
thymoma.
Materials and Methods
In vivo study
Scintigraphy with [111In-DTPA-d-Phe1]octreotide was performed as
previously reported (21). Briefly, planar and single photon emission
tomography (SPECT) images of the chest were obtained 24 h after the
injection of 228 megabecquerels [111In-DTPA-d-Phe1]octreotide
(Mallinkrodt, Inc., Petten, The Netherlands). Imaging studies were per-
formed using a two-headed g-camera (Picker 2000, Picker Instruments,
Cleveland, OH) for planar imaging and a three-headed g-camera (Picker
3000) for SPECT studies, both equipped with a medium energy colli-
mator. Acquisition time for planar spot images was 15 min.
Samples
The thymoma was surgically removed from a female patient (age, 55
yr). Samples from this tumor and from three normal thymuses (from
children undergoing cardiac surgery) were used in the present study.
The protocol was in accordance with the Helsinki Doctrine on Human
Experimentation. Informed consent was obtained from the patients or
their parents. Samples were taken directly at the operation, quickly
frozen on dry ice, and stored at 280 C for autoradiographic and RT-PCR
studies or fixed in 10% paraformaldehyde overnight for immunohisto-
chemistry. An additional specimen of the tumor was used for the es-
tablishment of a primary culture.
SS receptor autoradiography and RT-PCR
Receptor autoradiography was carried out on 10-micrometer thick
cryostat sections using [125I-Tyr11]SS-14 and [125I-Tyr3]octreotide as ra-
dioligands (SA, ;2000 Ci/mmol) as previously described (18). RT-PCR
was performed as previously reported (18). The sizes of PCR products
were 318, 332, 651, 221, 323, 223, 349, and 762 bp, for sst1, sst2A, sst2B, sst3,
sst4, sst5, SS, and b-actin, respectively.
SS receptor binding studies
The method of membrane isolation and the reaction conditions were
described previously (18). [125I-Tyr11]SS-14 and [125I-Tyr3]octreotide
were used as radioligands.
Immunohistochemical localization of sst1, sst2A, and
sst3 receptors
Paraffin-embedded sections (5 mm) were deparaffinized, rehydrated,
exposed to microwave heating (in citric acid buffer) at 100 C for 15 min,
rinsed in tap water followed by phosphate buffer solution, and subse-
quently incubated for 15 min in normal goat serum (1:10 dilution in
phosphate buffer solution and 5% BSA). The sections were then incu-
bated overnight at 4 C with the sst1 (R1–201) and sst2A (R2–88) antibodies
(gifts from Dr. A. Scho¨nbrunn) (22, 23) in a dilution of 1:500 (12) and with
the sst3 antibodies (Biotrend, Cologne, Germany) in a dilution of 1:3000.
Finally, a standard streptavidin-biotinylated alkaline phosphatase or
peroxidase complex (ABC kit, Biogenix, San Ramon, CA) was used
according to the manufacturer’s recommendations to visualize the
bound antibodies. Negative controls for immunohistochemistry in-
cluded 1) omission of the primary antibody, and 2) preabsorption of the
antibodies with the respective immunizing receptor peptides (at a con-
centration of 100 nmol/L).
Cell dispersion and cell culture
Normal and neoplastic TEC were isolated as previously described
(18). Briefly, the thymoma tissue was enzymatically dissociated with
collagenase (Sigma, St. Louis, MO; 2 mg/mL) for 1 h at 37 C. The
dispersed cells were precultured for 5–7 days in 15 mg/cm2 collagen
type I (Collagen S, type I, Roche Molecular Biochemicals, Mannheim,
Germany)-precoated 75-cm2 flasks (Costar, Cambridge, MA) at a density
of 5 3 106 cells/flask in 10 mL culture medium. The culture medium,
the same as that used during the experiments, was MEM d-valine (Life
Technologies, Inc., Paisley, Scotland) supplemented with 10% FCS, pen-
icillin (105 U/L), fungizone (0.5 mg/mL), and l-glutamine (2 mmol/L).
The pH of the medium was adjusted to 7.4. The cells were cultured at
37 C in a humid CO2 incubator. After this period, cell viability detected
by trypan blue exclusion was 90%, and the cells that had not attached
to the flasks, mainly thymocytes, were harvested.
The isolation of epithelial cells was indirectly performed using sheep
antimouse IgG-coated magnetic beads and an ASO2 antihuman fibro-
blast primary antibody kit (Dianova GmbH, Hamburg, Germany). This
mouse monoclonal antibody reacts specifically with membrane-bound
protein of human fibroblasts of different origins. The magnetic beads
were coated with the specific primary antibody and mixed with the
target cell suspension to form bead-rosetted cells (fibroblasts), which
were collected at the tube wall and isolated using a magnetic separator
rack. For a complete negative selection, the supernatant, containing the
epithelial cells that were not bound to the beads was treated once again
with the coated beads. This remaining suspension containing isolated
epithelial cells was used for the experiments. The cells (20,000/well)
were seeded in 1 mL culture medium in 24-well collagen type I-pre-
coated plates (Costar) and allowed to attach for 24 h. Thereafter, test
substances were added, and the cells were incubated for 72 h. Cell
proliferation was measured by adding 1 mCi [methyl-3H]thymidine (91
Ci/mmol; Amersham Pharmacia Biotech, Houten, The Netherlands)/
well during the last 24 h, as described in detail previously (18). For
RT-PCR studies, neoplastic TEC were seeded in collagen-coated flasks
(see above) and grown to confluence. Thereafter, the cells were har-
vested, and mRNA was isolated as described previously (18). For keratin
staining, cells were cultured on collagen-coated glass coverslips. The
cells were fixed for 10 min with methanol at the end of the incubation
period. Cytokeratin staining was performed with a PAP Kit System
(code K518, DAKO Corp., Glostrup, Denmark). Cultured thymocytes
were collected and processed for mRNA analysis by RT-PCR as previ-
ously described (18).
Test substances
SS-14 (Bachem, Hannover, Germany) and octreotide (Novartis, Basel,
Switzerland) were used at a concentration of 10 nmol/L.
Statistical analysis
Data are expressed as the mean 6 sem. Binding experiments were
performed at least twice, and the data shown for the displacement study
are derived from triplicate values. In functional studies, there were four
wells per treatment group. The data were analyzed by ANOVA to
determine overall differences between treatment groups. When signif-
icant differences were found, a comparison between treatment groups
was made using the Newman-Keuls test. SSR binding data were ana-
lyzed by the method of Scatchard.
Results
Scintigraphy with [111In-DTPA-D-Phe1]octreotide
A high uptake of [111In-DTPA-d-Phe1]octreotide was de-
tected after 24 h in the mediastinum (Fig. 1, A and B). Com-
puted tomographic scanning of the chest confirmed the di-
agnosis of thymic enlargement (Fig. 1C).
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SS and SSR (subtype) expression
At autoradiography, no specific binding of [125I-Tyr11]SS-
14 or [125I-Tyr3]octreotide was found in the thymoma (data
not shown). However, Scatchard analysis of [125I-Tyr11]SS-14
binding on an enriched membrane preparation of the thy-
moma tissue revealed high affinity binding sites with an
apparent Kd of 47.5 6 2.5 pmol/L and a low maximum
binding capacity (Bmax) of 23.5 6 2.5 fmol/mg membrane
protein. Figure 2A shows a representative experiment. No
specific binding was detectable on the tumor-derived cul-
tured thymocytes. In addition, octreotide (100 nm) displaced
[125I-Tyr11]SS-14 binding on membrane preparations of the
thymoma tissue significantly less compared with SS-14
(49.5% vs. 90.8%, respectively; Fig. 2B). On normal human
thymus membranes high affinity binding sites for [125I-
Tyr3]octreotide were detected [Kd, 200 6 70 pmol/L; Bmax,
4.7 6 0.3 fmol/mg membrane protein (mean 6 sem)].
By RT-PCR, sst1, sst2A, and a predominant sst3 mRNA
expression was detected in the thymoma tissue (Table 1).
Conversely, mRNAs encoding for SS, sst2B, sst4, and sst5 were
absent (Table 1). In the cultured neoplastic TEC, RT-PCR
analysis showed the presence of sst3 mRNA only (Table 1).
In cultured thymocytes only mRNA for b-actin was detected
(Table 1). As previously described (18), the normal thymus
expressed SS, sst1, sst2A, and sst3 mRNAs, whereas cultured
TEC expressed SS, sst1, and sst2A mRNAs (Table 1). By im-
munohistochemistry, a high immunoreactivity for sst3 re-
ceptors and a very weak immunostaining for sst1, but not for
sst2A, receptors was observed on the tumor cells (Fig. 3, A and
C). sst2A was weakly expressed in the stroma, mainly on
endothelium of few small intratumoral vessels (Fig. 3B). In
all cases the immunostaining could be completely abolished
by preabsorption with 100 nmol/L of the respective antigen
peptides (Fig. 3, D, E, and F).
In vitro effect of SS and octreotide on [3H]thymidine
incorporation of cultured neoplastic TEC
SS-14 (10 nm) and the SS analog octreotide (10 nm) sig-
nificantly inhibited [3H]thymidine incorporation by 40.6%
and 43.2%, respectively, in the cultured tumor cells (Fig. 4).
The epithelial origin of the cultured tumor cells was con-
firmed by immunocytochemical staining for cytokeratin that
revealed a 100% pure epithelial cell culture.
Discussion
Human thymoma is the most common tumor of the an-
terio-superior mediastinum and is composed of cytologically
bland, neoplastic TEC accompanied by a variable admixture
of benign lymphocytes (24). This tumor is frequently asso-
ciated with paraneoplastic phenomena, such as myasthenia
gravis, and/or other autoimmune-related disorders and he-
matological abnormalities (24). The microenvironment is ab-
normal in thymoma, and it differs from the normal thymus
in the prevalence of cortical areas and the deficiency of med-
ullary ones (25).
A high in vivo uptake of [111In-DTPA-d-Phe1]octreotide
has been detected in patients bearing thymoma or thymic
carcinoid, whereas the normal or hyperplastic thymus is
FIG. 1. A, Planar images of the chest 24 h after injection of [111In-
DTPA-D-Phe1]octreotide. Anterior (left) and posterior (right) views.
There is normal uptake in the thyroid and some accumulation in the
nose region due to common cold. An abnormal uptake in the region of
the left hilum is seen. B, Transversal SPECT images of the chest 24 h
post-injection. Images are from cranial to caudal. The left side of the
images represents the right side of the patient. In the top row, the
accumulation at the site of the thymoma is seen, located left-sided in
the anterior mediastinum. The last two images in the bottom row
show uptake in the liver. C, Computed tomographic scan of the chest.
The arrows indicate the extent of the thymic mass.
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not visualized (20, 26). Moreover, successful treatments
with octreotide and prednisone and with octreotide alone
have been reported in two patients with thymoma (19, 20).
In one case the treatment resulted in both tumor size
reduction and an improvement in the autoimmune-related
disease (19). The precise mechanisms involved in this ef-
fect are unclear, however. In a previous study, using in
vitro SSR autoradiography, Reubi et al. did not find SS-
binding sites in four thymomas of undefined histological
subtype, whereas SSR receptors were detectable in the
normal thymus (27). The lack of in vitro detection of SSR
in human thymoma seems in contrast with the compelling
evidence that tumors originating from SSR-positive tis-
sues generally express SSR (8, 28).
We have recently characterized SSR subtype expression in
the normal human thymus (18). sst1 and sst2A mRNAs were
expressed in the thymic tissue and isolated TEC, whereas sst3
mRNA was detectable in thymic tissue only and not on
enriched cultured TEC or cultured thymocytes (18). As sev-
eral different subsets of epithelial cells and thymocytes have
been described within the human thymus, the sst3 receptor
might be expressed on another cell subset or might undergo
FIG. 2. Expression of SSR in a mem-
brane preparation of the human thy-
moma. A, Saturation curves indicate
total (f), nonspecific (l), and specific
(F) binding of [125I-Tyr11]SS-14. Inset,
Scatchard analysis of [125I-Tyr11]SS-
14 binding to thymoma tissue mem-
branes (Kd, 50 pmol/L; Bmax, 21
fmol/mg membrane protein). B, Dis-
placement of [125I-Tyr11]SS-14 bind-
ing by SS-14 (100 nm; ^) and oct-
reotide (100 nm; f). *, P , 0.01 vs.
control; #, P , 0.01 vs. SS-14. Control,
922.3 6 3.2 cpm; SS-14, 84.7 6 4.7
cpm; octreotide, 465.7 6 14 cpm. Data
are derived from triplicate values and
are the mean 6 SEM.
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rapid down-regulation during culturing. In fact, it is well
known that the expression of neuropeptide receptors on
immune cells is dynamically regulated and depends on the
traffic of these cells through and within lymphoid compart-
ments and homing in the tissues (29, 30). Moreover, prelim-
inary data show sst2A immunoreactivity on stromal cells in
the medullary compartment of normal human thymus (31).
All of these findings are in agreement with the evidence of
a strong compartmentalization of neuroendocrine peptide
receptors in lymphoid tissue (32).
In the present report we found a high uptake of [111In-
DTPA-d-Phe1]octreotide in a patient with cortical thymoma
and, in agreement with the study by Reubi et al. (27), a lack
of SSR-binding sites by autoradiography performed on cry-
ostat sections from the tumor tissue. However, we were able
to detect a very low density of specific high affinity binding
sites of [125I-Tyr11]SS-14 on an enriched membrane prepara-
tion from the thymoma tissue. By RT-PCR, we found mRNAs
encoding for sst1, sst2A, and sst3 in the thymoma tissue,
whereas mRNA encoding for sst3 was detectable in primary
cultured neoplastic cells. Conversely, no binding was de-
tectable, and no mRNAs encoding for SSR subtypes were
found on the tumor-derived cultured thymocytes. Conso-
nant with the presence of sst1 mRNA and the low affinity of
octreotide for sst3 receptors, we found that octreotide only
partially displaced [125I-Tyr11]SS-14 binding on cell mem-
brane from this tumor. To further characterize the hetero-
geneous expression of SSR subtypes in this tumor, we used
three recently developed polyclonal SSR antibodies, highly
specific for sst1, sst2A, and sst3 receptors (11, 22, 23). By
immunohistochemistry, we observed a high immunoreac-
tivity for sst3 receptors and a very weak expression of sst1
receptors on the tumor tissue. Conversely, the tumor cells did
not express sst2A receptors, whereas sst2A immunoreactivity
was localized in the stroma, mainly on the endothelium of
scattered small intratumoral vessels. These findings confirm
the predominant presence of sst3 in this tumor. In fact, the
mRNA encoding for this protein has been detected by RT-
PCR on both tumor tissue and cultured tumor cells, and our
hypothesis is that this cortical thymoma might have arisen
from a subset of thymic sst3-expressing cells. However, the
diffuse immunoreactivity for sst3 in the tumor tissue suggests
the presence of this SSR subtype on reactive thymocytes as
well. Although mRNA encoding for sst3 was undetectable in
cultured thymocytes from both thymoma and normal thy-
mus, our recent observation showed the presence of SS-
binding sites on freshly isolated thymocytes (31). This find-
ing might explain the diffuse immunoreactivity for sst3 in the
thymoma and confirm the evidence that neuropeptide re-
ceptor expression in lymphoid tissues might rapidly change
in conditions different from those in the natural microenvi-
ronment (33).
sst3 receptors have been shown to display the highest
amount of agonist-dependent receptor internalization com-
pared to the other SSR subtypes (34). Although the affinity
of octapeptide SS analogs for sst3 is lower compared with that
for sst2, the high internalization of sst3 receptors might be the
possible mechanism regulating the in vivo uptake of [111In-
DTPA-d-Phe1]octreotide within thymomas. Indeed, the
present study demonstrates that sst3 is the subtype predom-
inantly expressed in this tumor, displaying a significant in
vivo uptake of [111In-DTPA-d-Phe1]octreotide. Another sug-
gestive hypothesis, which can not be completely excluded, is
the presence of a novel unidentified SSR involved in deter-
mining the in vivo uptake of the radiotracer.
Cell subsets containing neuropeptide hormones are
present in the cortical areas of normal thymus as well as in
thymoma (35). The identification of SS and its receptors in the
normal thymus strongly supports the paracrine actions of the
peptide in modulating the immuno- and/or neuroendocrine
functions in this organ (18, 27). The pattern of distribution of
SS-binding sites observed in normal thymus seems to be still
preserved in thymic hyperplasia associated with myasthenia
gravis, but seems to be lost in thymoma (27). Furthermore,
in the present case, SS mRNA was not detectable in either
thymoma tissue or the primary cultured tumor cells, whereas
it was detected in normal human thymic tissue and in normal
cultured TEC (18). This finding suggests that the loss of local
SS production might be implicated in the uncontrolled cell
growth and/or the tumor autoimmune-related diseases and
possible tumor pathogenesis. In support of this hypothesis,
we found that the in vitro administration of SS-14 and the SS
analog octreotide at high concentration (10 nmol/L) signif-
icantly inhibited [3H]thymidine incorporation in the cultured
tumor cells. Both compounds displayed a comparable ability
in inhibiting [3H]thymidine incorporation by cultured cells.
As SS-14 binds sst3 with higher affinity than octreotide, a
difference in the percentage of inhibition should have been
observed. However, taking into consideration that we mea-
sured the uptake of [3H]thymidine after 72 h, we might have
TABLE 1. Somatostatin and somatostatin receptor subtype mRNA expression in normal human thymus and in a cortical thymoma as
determined by RT-PCR
Samples
RT-PCR
sst1 sst2A sst2B sst3 sst4 sst5a SSb b-Actin
Normal human thymus 1 1 2 1 2 2 1 1
Normal TECc 1 1 2 2 2 2 1 1
Thymocytesd (normal thymus) 2 2 2 2 2 2 2 1
Thymoma 6 6 2 1 2 2 2 1
Neoplastic TEC 2 2 2 1 2 2 2 1
Thymocytesd (thymoma) 2 2 2 2 2 2 2 1
a Somatostatin receptor subtypes 1–5.
b Somatostatin.
c Thymic epithelial cells.
d Cultured thymocytes.
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FIG. 3. Immunohistochemical detection of sst1, sst2A, and sst3 receptors in the thymoma. Left: A, Weak diffuse sst1 immunoreactivity within
the tumor. Section developed with 3,39-diaminobenzidine; B, sst2A immunoreactivity located on the endothelium of an intratumoral vessel.
Section developed with 3,39-diaminobenzidine; C, high diffuse sst3 immunoreactivity within the tumor. Section developed with New Fucsine/
Naphtol AS-MX. Right: D–F, Adjacent sections showing displacement of immunostaining after the preabsorption of the antibodies with 100
nM of the respective peptide antigens. The sections are slightly counterstained with hematoxylin. Magnification, 3400. Bar, 25 mm.
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underestimated the true inhibition degree by SS-14 due to a
lower stability of the latter compound. The inhibition of cell
proliferation by SS-14 and octreotide, and the predominant
expression of sst3 in the thymoma are in line with emerging
data regarding signal transduction pathways linked to SSR
that show a cell cycle-dependent induction of apoptosis by
octreotide (36). Octreotide-induced apoptosis seems signaled
through the sst3 and associated with dephosphorylation-
dependent conformational change in wild-type p53 (37). Al-
though controversial data about alterations of p53 expression
have been reported in thymic epithelial tumors (38, 39), SS-
induced apoptosis might represent an additional mechanism
involved in the regulation of cell proliferation in human
thymus. Furthermore, this finding may form the basis for the
inhibition of tumor growth in patients with thymoma treated
with octreotide. As octreotide binds to sst2A, sst3, and sst5, but
not to sst1, and considering that in the present case sst2A and
sst5 are not expressed in the tumor cells, the in vitro effect of
SS and octreotide seems to be mediated directly by sst3.
In conclusion, although further investigations are re-
quired, the loss of SS production in combination with a
predominant expression of sst3 receptor in this thymoma
might be implicated in uncontrolled cell growth and tumor
pathogenesis. These data support the physiological para-
crine/autocrine role of SS in the human thymic microenvi-
ronment and indicate that a disturbance in this system might
be involved in the pathogenesis of thymic neoplasms. Fur-
thermore, SSRs are localized in different complementary cell
compartments in the normal and neoplastic human thymus.
At least three SSR subtypes seem to control neuroendocrine
function as well as the cell growth in this organ. Moreover,
the sst3 subtype may play an important role in determining
the uptake of [111In-DTPA-d-Phe1]octreotide during in vivo
SSR scintigraphy. The inhibition of cell proliferation by oc-
treotide through sst3 may explain the reported successful
treatment of thymoma with this SS analog. Finally, SSR scin-
tigraphy and SS analog treatment of thymomas may repre-
sent a new diagnostic and therapeutic approach to these
tumors.
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